Created by Guardant Health, the blood test, known as Shield, was able to detect 83% of colorectal cancers in studies but only 13% of dangerous polyps. Colonoscopies find approximately 95% of these ...
Anbogen, a clinical-stage biotech company, today announced a drug supply collaboration to evaluate the combination of Anbogen's HDAC inhibitor, ABT-301, with BeiGene's anti-PD-1 antibody tislelizumab, ...